Cronos Group Inc.

TSX:CRON.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$4.57 -0.27%

-$0.01 today

Market cap
$1.67B
Beta
1.25
P/E (TTM)
-488.1
EPS (TTM)
-$0.01
52W Low $2.54High $4.66

Volume 0.15M

Average 0.19M

CRON.TO EBITDA Margin

EBITDA as a percentage of revenue.

Cronos Group Inc.TSX: CRON.TO

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 48.4%

EBITDA Margin was 48.4% in Q1 FY2026, up 17.0 pp from a year earlier. On a trailing-twelve-month basis it was 30.0%, up 45.0 pp year over year. Over 3 fiscal years it widened by 105.2 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 42.8% for the fiscal year ending Dec 2026, up from -2.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
48.4%+68.0 pp QoQ
Last fiscal yearDec 2025
-2.0%+36.6 pp YoY
LTMMar 2026
30.0%+45.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+17.0 pp+3.0 pp-14.1 pp
1 year+36.6 pp+44.8 pp+8.2 pp
3 years+105.2 pp+38.1 pp-67.1 pp
5 years+36.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-2.0%
Year-over-year change
+36.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CRON.TO compares with its peers on the latest reported figures

  • CRON.TO's LTM Mar 2026 EBITDA Margin of 30.0% is the highest of the 6 companies compared; the peer median is 12.8%.
  • Its year-over-year change of +45.0 pp is the highest of 6, against a peer median of -0.2 pp.
  • Over three fiscal years its change of +105.2 pp compares with a peer median of +1.9 pp.
CRON.TO Competitors Peer median
EBITDA Margin for CRON.TO and competitors
Company Period LTM level YoY 3-year change
CRON.TOCronos Group Inc.LTM Mar 202630.0% +45.0 pp+105.2 pp
SIA.TOSienna Senior Living Inc.LTM Sep 202618.3% +3.3 pp+1.9 pp
WELL.TOWELL Health Technologies Corp.LTM Mar 202614.9% +8.6 pp-1.9 pp
GUD.TOKnight Therapeutics Inc.LTM Mar 202612.8% -5.8 pp+3.5 pp
EXE.TOExtendicare Inc.LTM Jun 202610.8% -0.2 pp+6.5 pp
TLRY.TOTilray Brands, Inc.LTM Feb 2026-156.2% -77.8 pp-219.8 pp
Peer median (excluding CRON.TO) 12.8%-0.2 pp+1.9 pp

Competitors are the stored peer set for CRON.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue64.02M87.54M87.03M117.5M149.15M
Cost of Revenue81.47M71.96M75.15M87.05M87.45M
Gross Profit(17.45M)15.58M11.88M30.45M61.7M
Gross Margin-27.3%17.8%13.7%25.9%41.4%
Research & Development21.66M13.25M5.83M4.22M4.53M
Selling, General & Admin120.67M101.64M80.74M76.74M75.01M
Operating Expenses272.09M128.01M96.48M106.91M79.54M
Depreciation & Amortization13.36M11.52M7.44M8.84M14.48M
EBITDA(150.79M)(93.81M)(72.28M)(45.37M)(2.94M)
EBITDA Margin-235.5%-107.2%-83.0%-38.6%-2.0%
Operating Income(289.54M)(112.44M)(84.6M)(76.46M)(17.84M)
Operating Margin-452.2%-128.4%-97.2%-65.1%-12.0%
Interest Income8.92M21.84M52.07M49.52M40.66M
Interest Expense00000
Other Income / Expenses162.1M(9.66M)11.1M113.01M419.21K
Income Before Tax(127.44M)(122.1M)(73.49M)36.55M(17.42M)
Pre-Tax Margin-199.1%-139.5%-84.4%31.1%-11.7%
Income Tax Expense(427.41K)34.48M(3.23M)(3.44M)(14.44M)
Net Income(392.81M)(170.26M)(73.79M)41.04M(9.61M)
Net Margin-613.5%-194.5%-84.8%34.9%-6.4%
EPS (Basic)(0.34)(0.42)(0.18)0.10(0.03)
EPS (Diluted)(0.34)(0.42)(0.18)0.10(0.03)
Weighted Avg Shares369.73M370.39M380.96M382.16M383.47M
Weighted Avg Shares (Diluted)370.39M370.39M380.96M382.16M383.47M

Cronos Group Inc.

TSX:CRON.TO

Intrinsic Alpha fair value

Locked

Current Price

$4.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.